Bioxytran (BIXT) Free Cash Flow Growth (1y) (2011 - 2026)
Bioxytran (BIXT) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 38.94% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 96.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 152.82% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.34% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 58.53% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 31.57% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -377.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.60% |
| Dec 31, 2025 | -85.22% |
| Sep 30, 2025 | 43.61% |
| Jun 30, 2025 | -14.83% |
| Mar 31, 2025 | -52.71% |
| Dec 31, 2024 | -38.12% |
| Sep 30, 2024 | 78.53% |
| Jun 30, 2024 | 54.16% |
| Mar 31, 2024 | 41.37% |
| Dec 31, 2023 | 40.12% |
| Sep 30, 2023 | 52.34% |
| Jun 30, 2023 | 35.81% |
| Mar 31, 2023 | 72.97% |
| Dec 31, 2022 | -7.68% |
| Sep 30, 2022 | -398.98% |
| Jun 30, 2022 | 76.56% |
| Mar 31, 2022 | -76.79% |
| Dec 31, 2021 | 83.87% |
| Sep 30, 2021 | -1,128.35% |
| Jun 30, 2021 | -2,469.28% |